Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120.
J Virol Methods
; 249: 85-93, 2017 11.
Article
en En
| MEDLINE
| ID: mdl-28837840
ABSTRACT
Development of a HIV-1 vaccine is a major global priority. The yellow fever virus (YFV) attenuated vaccine 17D is among the most effective of currently used vaccines. However, the stability of the YFV17D vector when carrying non-flavivirus genes has been problematic. We have constructed and expressed HIV-1 Env in YFV17D with either single transmembrane (STM) or double transmembrane (DTM) YFV E protein domains for the development of anti-HIV antibodies. Here we describe modifications of the YFV17D vector such that HIV-1 Env gp120 is expressed in up to 5 passages in Vero cells. Immunization with recombinant YFV17D vector prime followed by HIV-1 CH505 TF gp120 protein boosts were able to induce neutralizing antibodies for a HIV-1 tier 1 isolate in mice. This modified YFV vector may be a starting point for constructing HIV-1 vaccine candidate priming vectors.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Virus de la Fiebre Amarilla
/
Proteína gp120 de Envoltorio del VIH
/
VIH-1
/
Vacunas contra el SIDA
Límite:
Animals
Idioma:
En
Revista:
J Virol Methods
Año:
2017
Tipo del documento:
Article